Celcuity Inc.
CELCNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$172.2M | −$113.3M | −$66.2M | −$39.4M | −$28.4M | −$9.6M |
| Net income | −$177.0M | −$111.8M | −$63.8M | −$40.4M | −$29.6M | −$9.5M |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M | $85.9M | $13.0M |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M | $17.2M | $1.3M |
| Equity | $100.6M | $115.6M | $139.8M | $133.8M | $68.7M | $11.7M |
| EPS (diluted) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | $-2.21 | — |
| Shares out. | 37.8M | 30.5M | 21.7M | 14.9M | 10.3M | 10.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −176.1%
- Return on assets
- −37.9%
- Return on capital (ROCE)
- −40.8%
- Liabilities / assets
- 78.4%
- Debt / equity
- 3.64×
- Book value / share
- $2.66
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.60distress
- Accruals / assets
- −5.1%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-06-30Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Phase 1/2Recruitingreadout ~2028-01Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase 3Recruitingreadout ~2029-03-31Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rtw Investments, LpPassive (13G)May 15, 2026
- Baker Bros. Advisors LpActivist (13D)Mar 24, 2026
- Growth Equity Opportunities 18 Vge, LlcActivist (13D)Mar 9, 2026
- Perceptive Advisors LlcPassive (13G)Feb 17, 2026
- Avoro Capital Advisors LlcPassive (13G)Feb 17, 2026
- Soleus Private Equity Fund Ii, L.P.Passive (13G)Feb 12, 2026
- Biotechnology Value Fund L PPassive (13G)Nov 14, 2025
- Sullivan Brian F.Passive (13G)Nov 13, 2025
- Laing Lance G.Passive (13G)Nov 13, 2025
- Commodore Capital LpPassive (13G)Feb 14, 2025
- Soleus Capital Master Fund, L.P.Passive (13G)Feb 11, 2025
- Blackrock, Inc.Passive (13G)Feb 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Buller Richard EDirector | May 19, 2026 | Gift | 1,029 | $0.00 |
| Dalvey DavidDirector | May 4, 2026 | Sell | 25,000 | $140.68 |
| Buller Richard EDirector | May 4, 2026 | Option exercise | 9,000 | $5.10 |
| Nigon RichardDirector | Apr 9, 2026 | Gift | 10,000 | $0.00 |
| Buller Richard EDirector | Mar 31, 2026 | Option exercise | 3,000 | $5.10 |
| Romp Charles RDirector | Feb 11, 2026 | Grant | 215 | $0.00 |
| Dalvey DavidDirector | Jan 27, 2026 | Sell | 20,000 | $120.03 |
| Nigon RichardDirector | Dec 15, 2025 | Gift | 19,975 | $0.00 |
| Buller Richard EDirector | Dec 5, 2025 | Option exercise | 3,000 | $5.50 |
| Furcht LeoDirector | Dec 4, 2025 | Option exercise | 250 | $7.60 |
| Buller Richard EDirector | Dec 1, 2025 | Option exercise | 1,100 | $14.83 |
| Dalvey DavidDirector | Nov 21, 2025 | Sell | 15,000 | $100.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.6M | 6.0 | +7.1% |
| Apr 30, 2026 | 8.9M | 11.2 | +1.4% |
| Apr 15, 2026 | 8.8M | 12.8 | +0.0% |
| Mar 31, 2026 | 8.8M | 11.1 | -3.6% |
| Mar 13, 2026 | 9.1M | 13.0 | +0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 18, 2026
- Results of operationsMay 14, 2026
- Regulation FD disclosure · Other material eventMay 1, 2026
- Results of operationsMar 25, 2026
- Director / officer change · Regulation FD disclosureFeb 12, 2026
- Regulation FD disclosure · Other material eventNov 17, 2025
- Results of operationsNov 12, 2025
- Regulation FD disclosure · Other material eventOct 20, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.